Merck & Co. Inc.’s silence on its proposed Rx-to-OTC Singulair switch since an FDA advisory panel recommended against approval could give multiple signals for that product in particular as well as the switch market in general.
Despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative, activity has been relatively “quiet” in 2015,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?